Combined use of 123I-labelled BCD-F9 and 4C4 monoclonal antibody with dissimilar specificity for breast cancer: implication for the detection limit of immunolymphoscintigraphy in the assessment of axillary lymph node metastases

MLA

R. Mandeville, et al. “Combined Use of 123I-Labelled BCD-F9 and 4C4 Monoclonal Antibody with Dissimilar Specificity for Breast Cancer: Implication for the Detection Limit of Immunolymphoscintigraphy in the Assessment of Axillary Lymph Node Metastases.” Nuclear Medicine Communications, vol. 15, no. 6, June 1994. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....5fdd6518c16faf2a5d243a6a4c05393b&authtype=sso&custid=ns315887.

APA

R. Mandeville, Ch. Schatten, K Czerwenka, Angelberger P, H Enzelsberger, N Pateisky, E Kubista, & Barrada M. (1994). Combined use of 123I-labelled BCD-F9 and 4C4 monoclonal antibody with dissimilar specificity for breast cancer: implication for the detection limit of immunolymphoscintigraphy in the assessment of axillary lymph node metastases. Nuclear Medicine Communications, 15(6).

Chicago

R. Mandeville, Ch. Schatten, K Czerwenka, Angelberger P, H Enzelsberger, N Pateisky, E Kubista, and Barrada M. 1994. “Combined Use of 123I-Labelled BCD-F9 and 4C4 Monoclonal Antibody with Dissimilar Specificity for Breast Cancer: Implication for the Detection Limit of Immunolymphoscintigraphy in the Assessment of Axillary Lymph Node Metastases.” Nuclear Medicine Communications 15 (6). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....5fdd6518c16faf2a5d243a6a4c05393b&authtype=sso&custid=ns315887.